Human Papillomavirus in Young People Epidemiological Research 2 (HYPER2)
Human Papillomavirus in Young People Epidemiological Research 2 (HYPER2)
Australia was one of the countries to implement a universal school-based male vaccination
 program - in 2013. This research project will examine the prevalence of HPV among young men
 who have sex with men (MSM) who have been offered school-based HPV vaccination.
HYPER-2, will be a cross-section study, using the same recruitment and testing strategies
 used in HYPER 1, which determined the prevalence of anal, genital and oral HPV among men who
 have sex with men aged 16-20 years. Given the differing age groups that will have been
 offered vaccination over the 2 study period, men aged 16-19 will be recruited in the first
 year (2017) and men aged 16-20 will be recruited in the second year (2018) to ensure that the
 participants included in the HYPER-2 study would have been eligible for the free male HPV
 vaccine in Australia. A total of 200 men will be recruited over a 2-year period, and HPV
 vaccination status for each participant will be verified against the National HPV Vaccination
 Program Register.

 This 2-year cross-sectional study will recruit men who report sex with men aged from 16 to 20
 years.
Inclusion Criteria:

 -  Men aged 16 to 20 (Must be aged 16-19 years from 1 January 2017 to 31 December 2017,
 and aged 16-20 years from 1 January 2018 to 31 December 2018)

 -  Report any previous type of sexual contact (including but not restricted to oral or
 anal sex) with at least one other man ever

 -  Able to complete all study requirements including questionnaire in English and
 completion of 2 visits

 -  Residing in Australia since 2013 (This is to ensure that males included in the study
 were present in Australia at the time HPV vaccination was offered)

 Exclusion Criteria:

 -  Transgender male